262 related articles for article (PubMed ID: 33096076)
1. Pharmacological activation of REV-ERBα improves nonalcoholic steatohepatitis by regulating intestinal permeability.
Ni Y; Zhao Y; Ma L; Wang Z; Ni L; Hu L; Fu Z
Metabolism; 2021 Jan; 114():154409. PubMed ID: 33096076
[TBL] [Abstract][Full Text] [Related]
2. Time-dependent effect of REV-ERBα agonist SR9009 on nonalcoholic steatohepatitis and gut microbiota in mice.
Ni Y; Nan S; Zheng L; Zhang L; Zhao Y; Fu Z
Chronobiol Int; 2023 Jun; 40(6):769-782. PubMed ID: 37161366
[TBL] [Abstract][Full Text] [Related]
3. SR9009 induces a REV-ERB dependent anti-small-cell lung cancer effect through inhibition of autophagy.
Shen W; Zhang W; Ye W; Wang H; Zhang Q; Shen J; Hong Q; Li X; Wen G; Wei T; Zhang J
Theranostics; 2020; 10(10):4466-4480. PubMed ID: 32292508
[No Abstract] [Full Text] [Related]
4. REV-ERB agonism suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss partially via FABP4 upregulation.
Song C; Tan P; Zhang Z; Wu W; Dong Y; Zhao L; Liu H; Guan H; Li F
FASEB J; 2018 Jun; 32(6):3215-3228. PubMed ID: 29401617
[TBL] [Abstract][Full Text] [Related]
5. Rev-erbα activation down-regulates hepatic Pck1 enzyme to lower plasma glucose in mice.
Yuan X; Dong D; Li Z; Wu B
Pharmacol Res; 2019 Mar; 141():310-318. PubMed ID: 30639375
[TBL] [Abstract][Full Text] [Related]
6. REV-ERBβ is required to maintain normal wakefulness and the wake-inducing effect of dual REV-ERB agonist SR9009.
Amador A; Kamenecka TM; Solt LA; Burris TP
Biochem Pharmacol; 2018 Apr; 150():1-8. PubMed ID: 29355503
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and Genetic Modulation of REV-ERB Activity and Expression Affects Orexigenic Gene Expression.
Amador A; Wang Y; Banerjee S; Kameneka TM; Solt LA; Burris TP
PLoS One; 2016; 11(3):e0151014. PubMed ID: 26963516
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological activation of REV-ERBα represses LPS-induced microglial activation through the NF-κB pathway.
Guo DK; Zhu Y; Sun HY; Xu XY; Zhang S; Hao ZB; Wang GH; Mu CC; Ren HG
Acta Pharmacol Sin; 2019 Jan; 40(1):26-34. PubMed ID: 29950615
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological modulation and genetic deletion of REV-ERBα and REV-ERBβ regulates dendritic cell development.
Amir M; Campbell S; Kamenecka TM; Solt LA
Biochem Biophys Res Commun; 2020 Jul; 527(4):1000-1007. PubMed ID: 32439175
[TBL] [Abstract][Full Text] [Related]
10. The role of SHP/REV-ERBα/CYP4A axis in the pathogenesis of alcohol-associated liver disease.
Yang Z; Smalling RV; Huang Y; Jiang Y; Kusumanchi P; Bogaert W; Wang L; Delker DA; Skill NJ; Han S; Zhang T; Ma J; Huda N; Liangpunsakul S
JCI Insight; 2021 Aug; 6(16):. PubMed ID: 34423788
[TBL] [Abstract][Full Text] [Related]
11. Qingrequzhuo capsule alleviated methionine and choline deficient diet-induced nonalcoholic steatohepatitis in mice through regulating gut microbiota, enhancing gut tight junction and inhibiting the activation of TLR4/NF-κB signaling pathway.
Lv S; Zhang Z; Su X; Li W; Wang X; Pan B; Li H; Zhang H; Wang Y
Front Endocrinol (Lausanne); 2022; 13():1106875. PubMed ID: 36743916
[TBL] [Abstract][Full Text] [Related]
12. Amelioration of non-alcoholic steatohepatitis by Qushi Huayu decoction is associated with inhibition of the intestinal mitogen-activated protein kinase pathway.
Leng J; Huang F; Hai Y; Tian H; Liu W; Fang Y; Hu Y; Peng J
Phytomedicine; 2020 Jan; 66():153135. PubMed ID: 31790895
[TBL] [Abstract][Full Text] [Related]
13. The Putatively Specific Synthetic REV-ERB Agonist SR9009 Inhibits IgE- and IL-33-Mediated Mast Cell Activation Independently of the Circadian Clock.
Ishimaru K; Nakajima S; Yu G; Nakamura Y; Nakao A
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31847374
[TBL] [Abstract][Full Text] [Related]
14. Western diet-induced increase in colonic bile acids compromises epithelial barrier in nonalcoholic steatohepatitis.
Gupta B; Liu Y; Chopyk DM; Rai RP; Desai C; Kumar P; Farris AB; Nusrat A; Parkos CA; Anania FA; Raeman R
FASEB J; 2020 May; 34(5):7089-7102. PubMed ID: 32275114
[TBL] [Abstract][Full Text] [Related]
15. REV-ERB agonism improves liver pathology in a mouse model of NASH.
Griffett K; Bedia-Diaz G; Elgendy B; Burris TP
PLoS One; 2020; 15(10):e0236000. PubMed ID: 33002003
[TBL] [Abstract][Full Text] [Related]
16. Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease.
Utzeri E; Usai P
World J Gastroenterol; 2017 Jun; 23(22):3954-3963. PubMed ID: 28652650
[TBL] [Abstract][Full Text] [Related]
17. SR9009 has REV-ERB-independent effects on cell proliferation and metabolism.
Dierickx P; Emmett MJ; Jiang C; Uehara K; Liu M; Adlanmerini M; Lazar MA
Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12147-12152. PubMed ID: 31127047
[TBL] [Abstract][Full Text] [Related]
18. Rev-erb agonist and TGF-β similarly affect autophagy but differentially regulate hepatic stellate cell fibrogenic phenotype.
Thomes PG; Brandon-Warner E; Li T; Donohue TM; Schrum LW
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):137-147. PubMed ID: 27840152
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of nuclear receptor REV-ERBs suppresses production of pronociceptive molecules in cultured spinal astrocytes and ameliorates mechanical hypersensitivity of inflammatory and neuropathic pain of mice.
Morioka N; Kodama K; Tomori M; Yoshikawa K; Saeki M; Nakamura Y; Zhang FF; Hisaoka-Nakashima K; Nakata Y
Brain Behav Immun; 2019 May; 78():116-130. PubMed ID: 30682503
[TBL] [Abstract][Full Text] [Related]
20. Repression of TXNIP-NLRP3 axis restores intestinal barrier function via inhibition of myeloperoxidase activity and oxidative stress in nonalcoholic steatohepatitis.
Bai RX; Xu YY; Qin G; Chen YM; Wang HF; Wang M; Du SY
J Cell Physiol; 2019 May; 234(5):7524-7538. PubMed ID: 30387131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
